Imidazolone compounds act as protein kinase inhibitors, particularly Dyrk1A, CLK1, and / or CLK4.

Abstract

The invention relates to a compound with the formula (I) where RJ is a (Ci-C6)alkyl group, a spiro(C5-Cn) bicyclic ring, a condensed phenyl group, a substituted phenyl group, an R'-L- group, where L is either a single bond or a (Ci-C)alkandiyl group, and R' is a (C3-Cs)cycloalkyl group, a (C1-C2)cycloalkyl group, a (Ci-Cs)hexeocycloalkyl group, or a (Cs-C)hexeoaryl group, or an R'-L- group, where L is a (Ci-C3)alkandiyl group, and R' is an arbitrary substituted phenyl group, and where R2 is a hydrogen atom or a (Ci-alkyl group or any pharmaceutical salt thereof. The invention relates to a pharmaceutical composition containing a compound with the formula (i) and a process for the production of such a compound as well as a synthesis intermediate of it. This is a meeting of substances.The invention also relates to a compound for use as a medicine, particularly in the treatment and / or prevention of cognitive impairment associated with Down syndrome; Alzheimer's disease; dementia; brain-related diseases; Parkinson's disease; CDKL5 deficiency disorder; Plielan-McDermid syndrome; autism; type 1 and type 2 diabetes mellitus; abnormal metabolism of folate and methionine; osteoarthritis; Duchenne muscular dystrophy; certain cancers; neuritis, diseases, anemia and viral and protozoal infections and in the regulation of body temperature.